INSILICO MEDICINE ANNOUNCES ORAL PRESENTATION AT ESMO 2026 FOR PHASE 1 CLINICAL STUDY OF ISM6331 IN MESOTHELIOMA AND ADVANCED SOLID TUMORS

Reuters · 3d ago

Please log in to view news